Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • unsolvedquestions
    Junior Member
    • Mar 2018
    • 1

    #1

    Urgent help needed

    Hi everyone. I am sorry for asking a question that may sound very trivial to many of you but I am new to this field and do not have a bioinformatics background. Actually WES was done for 4 tumor samples which showed a mapping rate of 70-85% after alignment with BWA. Now I am reading everywhere that Mapping rate must be >90% but I am getting a low mapping rate. I want to know what can be the possible reasons for getting such low mapping rate and can we proceed with variant calling with such low mapping rate. Will the variant calling data be acceptable?

    Thank you
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    While your mapping rate is lower (you could take a selection of reads that don't map and blast them at NCBI to figure out what they are) you should be able to proceed with further analysis. Assuming you have enough coverage to do SNP calling (>15-20x).

    Comment

    • gringer
      David Eccles (gringer)
      • May 2011
      • 845

      #3
      I'd recommend doing an analysis on the unmapped reads to make sure that they are not hitting something other than your intended target. With a tumour sample it's unlikely to be a contamination issue, but just in case, you could feed the unmapped reads through Centrifuge or OneCodex just to be sure of that.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-22-2026, 11:13 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 10:48 AM
      0 responses
      20 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      36 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      42 views
      0 reactions
      Last Post SEQadmin2  
      Working...